NCT Research

Personalized Medicine in Oncology Partnership

Between Roche and NCT Members

The joint NCT-Roche collaboration strives for the exploitation of mechanisms in cancer treatment with combinations of innovative medicines (including cancer immunotherapies) at exploratory development for measurable clinical response. To do so, Roche’s drug development and diagnostic skills for companion diagnostics will be matched with NCT’s medical expertise to unravel the biological events in the patient’s tumor and immune system.

A special focus will be set on the investigation of strong clinical benefit in individual patients as well as patients who progress very rapidly during treatment with new drugs or new drug combinations. Biomarker profiles and other relevant parameters of those patient groups will be compared to the whole patient population. The expected outcome has 2 important, but distinct impacts:

  1. Advance understanding of tumor biology by applying cutting edge technologies for tumor-host interactions in selected tumor types
  2. Development of new combination therapies based on pathway investigations and diagnostic test developments to select patients for the best treatment available.

Innovations in cancer drug development are increasingly supplementing the advances in surgery and modern radiation therapy. These innovations are mostly driven by continuously increased understanding of molecular mechanisms of pathogenesis. But even with these new treatment options, only a subset of all cancer patients are currently cured or long-term stabilized.

Targeted medicines in today's oncological therapy are characterized in a way that their targets on which they exert their effects are molecularly known and their role has been proven in the pathogenesis. This concept brings a new and additional step into patient management, the preselection step by a validated diagnostic testing method if an individual patient holds the target and will therefore become eligible for treatment.

 

News & Events

The „Personalised Medicine in Oncology Partnership“ between NCT and Roche has set itself the objective of addressing the question of exploring the biology of cancer patients at exploratory state of clinical development and/ or for extension of indications.

This will include investigations related to the genome, transcriptome, and the proteome, investigations about the immune status of the patients, clinical parameters, and analysis of the environment of the patients. A special focus will also be set on the quality and reproducibility of the analytical tools and diagnostic test platform.

Our joint efforts will help to develop new cancer drugs in a truly bench-to bedside collaboration with instant flow of medical relevant patient information to new drug design.
A Joint Steering Committee is composed of equal representation of Roche and NCT members (one DKFZ member, one University Hospital member). The tasks of the Joint Steering Committee are to manage, oversee, and coordinate the Parties’ relationship and to determine new areas and programs of cooperation under the Master Agreement.

The „Personalised Medicine in Oncology Partnership“ between NCT and Roche has set itself the objective of addressing the question of exploring the biology of cancer patients at exploratory state of clinical development and/ or for extension of indications. This will include investigations related to the genome, transcriptome, and the proteome, investigations about the immune status of the patients, clinical parameters, and analysis of the environment of the patients. A special focus will also be set on the quality and reproducibility of the analytical tools and diagnostic test platform. Our joint efforts will help to develop new cancer drugs in a truly bench-to bedside collaboration with instant flow of medical relevant patient information to new drug design.

NCT-Roche Program Office is responsible for

  • Support and facilitate the development of scientific and clinical collaborations across parties` departments and/or institutes
  • Support and oversee the joint Roche / Heidelberg project landscape
  • Under direction from the scientific or program teams: define new areas and Programs of cooperation for recommendation to the steering committee,
  • Including the preparation of new proposals for potential projects
  • Manage, review and report the progress of collaborative projects and activities
  • Towards achievement of the targets and results
  • Issue Management


Dr. Sigried Ziegler



Dr. Alexandra Farfsing



The Roche-NCT Joint Steering Committee (JSC) in the speakers corner during the "Innovations in Oncology Workshop" 2017.


Dr. Christian Rommel
Global Head Oncology Drug Discovery, F. Hoffmann-La Roche Ltd.

Dr. Stefan Frings

Medical Director, Roche Pharma AG

Prof. Dr. Christof von Kalle
Managing Director, NCT Heidelberg
Head of the Division of Translational Oncology, DKFZ/NCT

Prof. Dr. Dirk Jäger
Managing Director, NCT Heidelberg
Medical Director of the Department of Medical Oncology, Heidelberg University Hospital/NCT